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Background: The degree to which genetic or environmental factors are associated with early kidney damage
among African Americans (AAs) is unknown.
Methods: Among 462 AAs in the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS)
study, we examined the cross-sectional association between apolipoprotein L1 (APOL1) risk variants and income
with: 1) mildly reduced eGFR (<75 mL/min/1.73 m2, creatinine-cystatin C equation) and 2) elevated urine
albumin-to-creatinine ratio (ACR) (≥17 in men and ≥25 mg/g in women). High risk APOL1 status was defined by
2 copies of high-risk variants; low risk if 0 or 1 copy. Income groups were dichotomized as < $14,000/year (lowest
income group) or≥ $14,000/year. Logistic regression models were adjusted for age, sex, and % European ancestry.
Results: Overall, participants’ mean age was 47 years and 16% (n = 73) had high risk APOL1 status. Mean eGFR was
99 mL/min/1.73 m2. Mildly reduced eGFR was prevalent among 11% (n = 51). The lowest income group had higher
adjusted odds (aOR) of mildly reduced eGFR than the higher income group (aOR 1.8, 95% CI 1.2-2.7). High-risk APOL1
was not significantly associated with reduced eGFR (aOR 1.5, 95% CI 0.9-2.5). Among 301 participants with ACR data, 7%
(n = 21) had elevated ACR. Compared to low-risk, persons with high-risk APOL1 had higher odds of elevated ACR (aOR 3.8,
95% CI 2.0-7.3). Income was not significantly associated with elevated ACR (aOR 1.8, 95% CI 0.7-4.5). There were no
significant interactions between APOL1 and income.
Conclusions: Both genetic and socioeconomic factors may be important determinants of early kidney damage among
AAs.
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Apolipoprotein L1 (APOL1) belongs to a family of genes
which encode for lipoproteins that are likely involved in
the transport and metabolism of lipids. Unlike others in
this gene family, APOL1 possesses a signal sequence that
allows for it to be exported out of the cell. Once extra-
cellular, APOL1 associates with HDL particles and may
play a role in programmed cell death [1,2]. While they
confer protection against the parasite Trypanosoma bru-
cei, genetic variants in the APOL1 region of chromo-
some 22 have been identified as major determinants of* Correspondence: dcrews1@jhmi.edu
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The two most common high-risk variants of APOL1, G1
and G2, are only seen among individuals of West
African descent, with approximately 12% of African
Americans having two high-risk variants. In contrast,
these high-risk variants are virtually nonexistent among
Asians, Europeans, and Hispanics [3,4]. Multiple studies
have now shown that, compared to those with zero or one
high-risk variant, the presence of two high-risk variants is
associated with advanced kidney disease in the setting
of focal segmental glomerulosclerosis [3], hypertension-
attributed nephropathy [5] and HIV-associated nephropa-
thy [6]. High-risk APOL1 is also associated with progres-
sion of established CKD, independent of diabetes status [7].
Less is known about the relation of APOL1 and early
kidney damage. Some studies have shown associationsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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prevalent high ACR [8] and very high ACR [9] among
populations with largely preserved eGFR.
However, importantly, not all African Americans with
two high-risk variants develop incident [10] or progres-
sive CKD [7], suggesting that a “second hit” may be re-
quired. This second hit may be environmental, including
infectious factors (as in the case of HIV associated ne-
phropathy), as well as factors related to socioeconomic
status (SES) or comorbid disease burden. Multiple stud-
ies have found that adjustment for SES attenuates ob-
served disparities in kidney-related outcomes between
African Americans and whites, suggesting that factors
related to low SES contribute to the excess risk of ad-
vanced CKD and ESRD seen among African Americans
[11,12]. Some studies have found that low SES correlates
more strongly with CKD/ESRD among African Americans
than whites, further supporting the notion of environmental
contributions to racial disparities [13-15]. There are many
possible mechanisms through which SES could contribute
to these disparities, and several models have been proposed
[11,16]. For example, limited availability of healthful foods
in the neighborhoods of many low SES African Americans
could lead to poor dietary patterns [17,18], which could ul-
timately affect CKD risk– particularly given the growing
body of evidence supporting that dietary patterns rich in
fruits and vegetables could be kidney protective [19-21].
Despite recent advances in understanding genetic contri-
butions to racial disparities in CKD, questions still remain,
including the relation of genetic factors to the variation in
GFR among populations largely free of established CKD
[8]. Furthermore, the possible role of gene-environment
interactions in determining early kidney disease among
African Americans has not been well-explored. Therefore,
the objective of this study was to evaluate whether genetic
factors, environmental factors (SES), or their interaction
are associated with markers of renal dysfunction among
persons without established CKD in an urban population
of predominantly low income African Americans.Methods
Healthy Aging in Neighborhoods of Diversity across the
Life Span (HANDLS): design and population
We examined cross-sectional data from the National In-
stitute on Aging (NIA), HANDLS study. HANDLS is a
community-based cohort study examining the influences
of race and SES on the development of health disparities
among minority and lower SES subpopulations. This co-
hort, recruited between 2004 and 2008, is comprised of
self-identified African Americans and whites 30–64 years
of age at baseline, from 13 Baltimore, MD neighborhoods
selected to reflect socioeconomic and racial diversity. Each
participant provided informed consent, and the NationalInstitute of Environmental Health Sciences Institutional
Review Board approved the study protocol [22].
The total HANDLS population is 3,720. For the pur-
poses of our study, we restricted our analysis to African-
American participants (N = 2200) who were genotyped
for APOL1 (N = 1024), underwent baseline serum cys-
tatin C (N = 848) and serum creatinine measurements
(N = 625), and reported their annual household income
(final N = 462). Analyses of urinary albumin to creatinine
ratio were restricted to participants who also underwent
baseline urine assessments (N = 301).
HANDLS: measurements and definitions
Demographic data, including age, sex, race, employment,
educational and insurance status, and annual household
income were obtained during an initial household survey
by self-report. Poverty status was also determined at
baseline and was based on reported annual household
income below or above 125% of the 2004 US Depart-
ment of Health and Human Services poverty guideline
[23].
A health care provider in a mobile research vehicle ob-
tained participants’ medical and social histories and per-
formed physical examinations. Hypertension was defined
as an average of seated and standing systolic blood pres-
sure ≥140 mm Hg, an average of seated and standing
diastolic blood pressure ≥90 mm Hg [24], a history of
blood pressure medication use, and/or a self-report of a
history of hypertension. Cardiovascular disease was de-
fined as a self-report of a history of congestive heart failure,
enlarged heart, angina, chest pain, myocardial infarction,
coronary artery disease, mini-stroke, or cerebrovascular ac-
cident. Height and weight were measured and used to cal-
culate BMI to determine the presence of obesity, defined as
BMI ≥30.
Fasting venous blood specimens and spot urine sam-
ples were also collected in the mobile research vehicle
and analyzed at the NIA Clinical Research Branch Core
Laboratory (Baltimore, MD, USA) and Quest Diagnostics
Inc. (Baltimore, MD and Chantilly, VA, USA). Diabetes
mellitus was defined as a fasting plasma glucose con-
centration of ≥126 mg/dl (7.0 mmol/l), Hemoglobin
A1c ≥ 6.5% or self-report of diabetes. Serum creatinine
was measured at Quest Diagnostics Inc. by isotope dilu-
tion mass spectrometry (Olympus America Inc., Melville,
NY, USA) and standardized to the reference laboratory at
the Cleveland Clinic. Serum cystatin C assays were run in
collaboration with the Department of Pathology at the
University of Maryland on the Dimension Vista® system
from Siemens (Glasgow, DE) using the Flex® reagent cart-
ridge. The serum creatinine and cystatin C were used to
estimate GFR using the combined creatinine-cystatin C
equation (eGFR) [25,26]. Urinary albumin to creatinine
measures were performed at Quest Diagnostics Inc. using
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Seattle, Wash. USA).
Percent European ancestry was estimated with STRUC-
TURE software that uses genotype data to assign individ-
uals to a population of origin. We entered 2000 ancestry
informative markers into our model to estimate the percent
European ancestry of study participants [27].
APOL1 Genotyping, imputation, and quality control
A total of 1024 study participants were successfully ge-
notyped using the Illumina 1 M single-nucleotide poly-
morphism (SNP) genotyping array, passing inclusion
criteria into the study. Initial inclusion criteria includes
concordance between self-reported sex and sex estimated
from X chromosome heterogeneity, > 95% genotype call
rate per participant, concordance between self-reported
African ancestry and ancestry confirmed by analyses of ge-
notyped SNPs, and no cryptic relatedness to any other
samples at a level of proportional sharing of genotypes >
15%. In addition, SNPs with Hardy-Weinberg equilibrium
p-value > 1 x 10−7, missing by haplotype p-value > 1 x 10−7,
minor allele frequency > 0.01, and call rate > 95% were in-
cluded. Quality control was conducted using PLINK 1.06
[28]. Genotypes that passed quality control criteria were
used for genotype imputation. Imputation was performed
using MACH and minimac software (http://www.sph.
umich.edu/csg/abecasis/mach/) based on phase 1 alpha
freeze version 3 data of the 1000 Genomes Project multi-
ethnic panel. Imputed SNP dosages and best guess geno-
types for rs73885319, rs60910145, and rs71785313 in
APOL1 gene were extracted from the imputation dataset to
generate G1 and G2 APOL1 risk haplotypes. Imputation
quality indicated by R2 estimates in MACH for rs73885319,
rs60910145, and rs71785313 were 0.84, 0.84, and 0.94, re-
spectively. An R2 > 0.30 indicates good accuracy of genotype
imputation. The linkage disequilibrium (LD) values be-
tween rs73885319 and rs60910145 were r2 = 1.0 and
D’ = 1.0, indicating the SNPs were in perfect LD.
Exposures of interest
The two primary exposures we examined were APOL1
and annual household income. Given previous studies
have shown the association between risk of kidney disease
and APOL1 to follow a recessive mode of inheritance
[3,6,7,9], we treated APOL1 as a dichotomous variable with
participants defined as low risk APOL1 (0 or 1 high risk
variant) or high risk APOL1 (2 high risk variants).
We created quintiles of annual household income in
order to better delineate differences in income, with 1
corresponding to the lowest quintile, because the major-
ity of our cohort lived in poverty (72%). For the purposes
of analysis, we divided these quintiles into two groups.
The first group included those who fell into income
quintiles <3, which corresponded to an annual householdincome < $14,000/year and from here on will be referred
to as the ‘lowest income group’. The second group in-
cluded those who fell into income quintiles ≥3, which cor-
responded to an annual household income ≥ $14,000/year,
here on referred to as the ‘higher income group’.Outcome measures
The primary outcomes of our study were 1) mildly re-
duced eGFR, defined as eGFRcys < 75 mL/min/1.73 m2,
as this threshold is associated with higher risk of ESRD,
death and cardiovascular disease2 [25], and 2) high urin-
ary albumin to creatinine ratio (ACR), defined as ACR ≥
17 mg/g in men and ≥ 25 mg/g in women [29]. We also
performed additional analyses of significantly reduced
eGFR (<60 mL/min/1.73 m2) and high ACR (≥30 mg/g).Statistical analyses
We examined participant characteristics stratified by
APOL1 status and then by income status. To evaluate
for any significant differences in these characteristics, t-
tests were used for continuous variables, and Fisher’s
exact tests were used for categorical variables.
We used multivariable logistic regression models to
determine the relationship of APOL1 and income with
our outcomes. We created separate models for the asso-
ciation of APOL1 with the outcome of interest and the
association of income with the outcome of interest.
Next, we created a combined model that included both
APOL1 and income as exposures, and then determined
the association of each individual exposure with the out-
come of interest. This combined model was then adjusted
for age, sex, and % European ancestry. The unadjusted
and adjusted models were tested for potential effect modi-
fication using interaction terms for APOL1 × income. We
also assessed the variance in early kidney damage ex-
plained by APOL1 risk variants and income status by
quantifying the difference in Nagelkerke’s R2 value from
the adjusted logistic regression model (which included
age, sex and % European ancestry) with and without the
inclusion of APOL1 or income.Sensitivity analyses
To assess whether our results varied by choice of pri-
mary measure of SES, we conducted several sensitivity
analyses. We analyzed our primary outcomes (eGFR <
75 and albuminuria) substituting income, separately,
with education level (dichotomized by high school
diploma or equivalency), employment status (based on
employment in the past month), health insurance
coverage (yes versus no), and regular source of health
care (yes versus no).
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Participant characteristics
A total of 462 HANDLS participants were included in
our sample. Those that were not included were of simi-
lar age and sex as those included, however, poverty was
much less prevalent among those not included (40%) as
compared to those included (72%) in our analysis. Also,
notably, a total of 16% of participants in our sample had
high risk APOL1 status, compared to 8% in the full sample
(n = 1024) of African American HANDLS participants
who underwent genotyping. The mean age of participants
was 47.4 (SD 8.9) years and 57.4% were female (Table 1).
When stratified by APOL1 status, there were no signifi-
cant differences in socio-demographic, clinical (hyperten-
sion, systolic blood pressure, diabetes, cardiovascular
disease or total cholesterol) or behavioral factors. The me-
dian income in this sample fell between $17,500 and
$20,000, and the majority of participants lived in poverty.
When stratified by income above or below $14,000, those
in the lowest income group were more likely to be un-
employed and more likely to have smoked cigarettes than
the higher income participants (P < 0.05 for both). Also,
while non-significant, hypertension was more prevalent
among the lowest income group. The higher income
group had higher total cholesterol and obesity prevalence
than the lowest income participants (P < 0.05 for both).Table 1 Participant characteristics by APOL1 Risk group and i










Age (SD), years 462 47.6 (8.9) 45.9 (9.0) 0.123 47
Female, % 462 56.3 63.0 0.305 58
Percentage European Ancestry (SD),
%
462 17.4 (8.5) 16.7 (8.7) 0.570 17
Socioeconomic Factors
Less than high school education, % 462 33.9 30.1 0.590 30
Unemployed, % 411 40.9 39.3 0.888 66
Uninsured, % 411 38.3 30.1 0.234 42
No regular health care source, % 411 37.7 36.1 0.886 45
Clinical and Behavioral Factors
Hypertension, % 429 55.7 50.0 0.427 60
Systolic Blood Pressure, mean (SD),
mmHg
450 123 (18) 121 (16) 0.534 12
Diabetes, % 462 24.9 19.2 0.370 20
Cardiovascular Disease, % 461 17.8 19.2 0.742 21
Total Serum Cholesterol, mean (SD),
mg/dL
462 184 (48) 191 (43) 0.257 17
Obesity, % 457 41.3 38.9 0.794 34
Tobacco Use≥ 100 cigs, % 435 70.5 69.6 0.886 76Analyses of reduced eGFR
The mean eGFR of the sample was 99 mL/min/1.73 m2.
Estimated GFR in the high-risk group was lower than in
the low-risk APOL1 group, but the difference was not
statistically significant [96 (SD 23) versus 100 (SD 20); P =
0.2]. The overall prevalence of eGFR <75 mL/min/1.73 m2
was 11% (n = 51). Compared with persons with low-risk
APOL1, high-risk persons were at 50% higher odds of
eGFR < 75, but estimates did not reach statistical signifi-
cance (Table 2). There was a significantly greater odds of
reduced eGFR in the lowest income group compared to
the higher income group that was consistent in unadjusted
and adjusted models [adjusted odds ratio (aOR) 1.81, 95%
Confidence Interval (CI) 1.21, 2.72; p =0.004]. There was
no evidence of effect modification. Fully, 53% of partici-
pants with eGFR < 75 were among the lowest income
group while only 22% were in the high risk APOL1 group.
The variance in eGFR < 75 explained by the inclusion of
APOL1 in our model adjusted for age, sex and % European
ancestry was 0. 4% compared to 1.5% explained by the in-
clusion of income.
Estimated GFR <60 ml/min/1.73 m2 was prevalent
among 4.1% of participants, and high-risk APOL1 status
was strongly associated with this outcome (aOR 2.48,
95% CI 2.29- 2.68; p = <0.001) while the lowest income








.9 (8.9) 47.0 (8.9) 0.253
.9 56.3 0.631






2 (19) 122 (18) 0.891
.5 26.4 0.182
.1 15.9 0.175
8 (42) 190 (51) 0.007
.4 45.3 0.025
.8 66.3 0.023
Table 2 Odds of eGFR <75 or <60 ml/min/1.73 m2 by APOL1 risk group and income category, N = 462
Model – Variables Odds Ratios for eGFR < 75 (95%




Odds Ratios for eGFR < 60 (95%


















APOL1 1.55 (0.91, 2.63) ——— 2.59 (2.48, 2.70) ———








1.50 (0.90, 2.49) 1.81 (1.21, 2.72) 0.653 2.48 (2.29, 2.68) 1.06 (0.33, 3.36) 0.09
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groups, respectively. The variance in eGFR < 60 explained
by the inclusion of APOL1 in our adjusted model was 2.1%
compared to 0.1% explained by the inclusion of income.
There was some evidence of effect modification (p inter-
action 0.09 for APOL1 × income in our adjusted model)
(Table 3). In unadjusted (due to the low event rate) models
stratified by income group, high-risk APOL1 was associated
with greater odds of eGFR < 60 only in the lowest income
group (OR 5.81, 95% 2.32-14.55). There was no statistically
significant association with APOL1 in the higher income
group (OR 1.22, 95% 0.59-2.53).Analyses of elevated urinary albumin-to-creatinine
Among the 301 participants who provided a urine sam-
ple, the median urinary ACR was 0.8 mg/g [interquartile
range (IQR) 0.50-2.60]. A total of 7.0% of participants
had elevated ACR (defined by sex-specific cut points).
High-risk APOL1 status was strongly associated with
greater odds of elevated ACR (aOR 3.76, 95% CI 1.95, 7.25);
and there was a non-significant association of lower incomeTable 3 Association of APOL1 and income with sex-specific el
Model – Variables Odds Ratios for Elevated ACR (95%
High-risk versus Low-risk APOL1
variants
Individual Variables
APOL1 3.69 (2.01, 6.78)
Income ————
Additive Models
APOL1, Income Category 3.56 (2.06, 6.16)
+ Age, Sex, Percent European
ancestry
3.76 (1.95, 7.25)and elevated ACR, with no evidence of effect modification
(Table 4).
Among persons with elevated ACR, 29% were in the
high-risk APOL1 group and 33% were in the lowest in-
come group); and the majority had hypertension (85%)
and/or diabetes (57%). The variance in elevated ACR ex-
plained by the inclusion of APOL1 in our adjusted model
was 5.7% compared to 1.5% explained by the inclusion of
income. Subsequent inclusion of hypertension and diabetes
to our primary model, separately, explained 8.9% and 7.5%,
respectively, of the variance in elevated ACR.
A total of 11 (3.7%) participants had high ACR (≥30 mg/
g). In unadjusted models (due to a low event rate), high-
risk APOL1 status was associated with high ACR, however
estimates were not statistically significant (OR 3.19, 95%
CI 0.55-18.59). Income was not associated with high ACR
(OR 0.90, 95% CI 0.48-1.72).
Sensitivity analyses
Our analyses substituting income for other measures of
SES yielded results which were qualitatively similar to
our primary analyses, except in the case of our inclusionevated albumin-to-creatinine ratio (ACR), N = 301
Confidence Interval) n = 21 events P interaction
(APOL1 x Income)




1.79 (0.68, 4.74) 0.811
1.78 (0.70, 4.49) 0.727
Table 4 Sensitivity analysis
Model – Variables Odds Ratios for eGFR < 75
(95% Confidence Interval)




Odds Ratios for Elevated ACR
(95% Confidence Interval)

















APOL1, Education 1.60 (1.00, 2.57) 1.95 (1.50, 2.54) 0.4 3.89 (2.28, 6.63) 1.68 (0.34, 8.23) 0.823
APOL1,
Employment
2.06 (1.53, 2.78) 4.64 (3.40, 6.33) 0.017* 3.12 (1.73, 5.63) 1.32 (0.83, 2.08) 0.894
APOL1, Health
Insurance





1.91 (1.15, 3.17) 0.54 (0.31, 0.94) 0.871 3.09 (1.56, 6.13) 0.64 (0.14, 2.86) **could not be
determined
Note: Data on employment, health insurance and regular source of health care were missing for 11% in the eGFR < 75 models and for 17% of the ACR models. For
the eGFR < 75 models, these variables were missing in 16% of the high-risk APOL1 group compared to 10% of the low-risk group. For the ACR models, these variables
were missing in 25% of the high-risk APOL1 group compared to 15% of the low-risk group.
*High-risk APOL1 was associated with eGFR < 75 only among those who were unemployed [3.54 (1.98, 6.35)] compared to the employed [0.45 (0.13, 1.58)].
**Imbalance in strata.
Association of APOL1 and Other Indicators of Socioeconomic Status (SES) with eGFR < 75 ml/min/1.73 m2 or Sex-Specific Elevated Albumin-to-Creatinine Ratio (ACR).
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(Table 4). For these metrics of access to care, only high-
risk APOL1 was associated with greater odds of mildly
reduced eGFR or elevated ACR. There was some evidence
of effect modification noted, with high-risk APOL1 only be-
ing associated with greater odds of eGFR < 75 among un-
employed participants (p interaction = 0.017 for APOL1 ×
employment status).
Discussion
In this study, we evaluated a cohort of young African
Americans largely free of established CKD to examine
the relation of APOL1, income and early kidney disease.
We found that income, but not high-risk APOL1, was
significantly associated with mildly reduced kidney function.
Upon examining further reductions in kidney function
(eGFR < 60), the association of high-risk APOL1 and re-
duced kidney function was significant. We also found that
high-risk APOL1 status, but not income, was significantly
associated with elevated ACR. The associations of APOL1
with markers of early kidney disease did not vary by income
category, or vice versa.
Few other studies have examined the association of
APOL1 with milder forms of kidney disease and findings
have varied. Foster, et al. [10] performed a prospective
study examining a cohort of African Americans with no
CKD at baseline and found an increased risk for eGFR <
60 and progression to ESRD among those with the high-
risk genotype. Friedman, et al. [8] found a 3-fold in-
creased risk of eGFR < 60 and microalbuminuria associated
with high risk APOL1 among nondiabetic African
Americans in a cross-sectional study; however, this asso-
ciation did not persist among persons with diabetes.Freedman, et al. [9] examined these cross-sectional rela-
tionships in relatives of patients with non-diabetic ESRD.
They found a significant association between APOL1 and
macroalbuminuria, but not with microalbuminuria or
eGFR < 60. In aggregate, these studies and ours suggest
that high-risk APOL1 variants may be more strongly asso-
ciated with advanced and progressive kidney disease than
with early disease, arguing for a primary role of APOL1 as
a progression rather than initiation factor in CKD.
Recent advances have swung the pendulum of research
and clinical thought regarding the etiology of racial dis-
parities in kidney disease towards the role of genetic
contributions. The results of our study suggest that gen-
etic factors may not fully explain these disparities. In this
sample largely free of CKD, a large proportion of indi-
viduals with early kidney damage were among those
without high-risk APOL1 variants. Rather, diabetes and/
or hypertension were prevalent among the majority of
participants with early kidney damage. Thus, despite the
highly significant association between high-risk APOL1
and kidney disease among African Americans in mul-
tiple recent studies [3,4,7,10], it may not be the only
contributor to early kidney disease in this population.
Other factor(s), including those related to and influenced
by SES, may be the primary initiators of CKD among
African Americans. In our study, for example, we found
that only about a third of individuals with elevated ACR
had high-risk APOL1 variants, however, the overwhelm-
ing majority had hypertension. Therefore, early CKD
identification and treatment of modifiable risk factors,
such as hypertension, may offer the greatest opportunity
for reducing CKD disparities among minority and low
income populations.
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est compared to the higher income group is consistent with
prior studies implicating SES as a major predictor of early
kidney disease among African Americans [12,13]. Our ana-
lyses of other indicators of SES were generally consistent
with the income analyses, except our finding of no associ-
ation between access to care measures and eGFR < 75.
Here, reverse causality was possible, as individuals in poor
health (ie. with reduced kidney function and other chronic
illnesses) may be more able to obtain public health insur-
ance and may seek care more often than healthier persons.
There are multiple possible mechanisms through which
low SES could lead to increased risk of kidney disease, most
of which have yet to be thoroughly investigated. Aside from
its potential impact on receipt of high quality health care,
there are less obvious mechanisms, related to the social en-
vironment and psychosocial impact of low SES that may
contribute as well [30,31]. Future studies are warranted elu-
cidating pathways between low SES and kidney disease.
The limitations of our study should be considered.
First, its cross-sectional design disallows direct causal in-
ferences regarding the associations examined, and thus,
longitudinal studies of this kind are needed. Second, des-
pite our stratifying participants around an annual income
of $14,000, our study population was largely comprised of
low income individuals, which may have influenced our
results. Third, we lacked complete data on some variables
included in our sensitivity analyses. Finally, our relatively
low event rate for early kidney damage did not allow adjust-
ment for multiple covariates, or more granular analyses of
income levels; and unmeasured confounders, particularly of
the association of income and early kidney disease, are
likely. Our power to detect statistically significant differ-
ences was limited in some of our models (Additional file 1).
We included adjustment for a parsimonious set of variables
despite the low event rate, and found that this did not sub-
stantially alter the point estimates of our univariate models.
While our findings can serve to generate hypotheses, larger
studies more representative of all African Americans are
warranted addressing these relationships among well-
characterized populations with a greater range of kidney
disease.
Conclusions
Our study is one of few examining the association of
both genetic and environmental factors with early kidney
damage [32]. In a population of urban-dwelling, primarily
low-income African Americans, we found that genetic fac-
tors were significantly associated with albuminuria and
significantly reduced eGFR, however, income level was a
correlate of less severe markers of early kidney damage.
Thorough examination of the burden of CKD among
African Americans may require consideration of both
genetic as well as environmental factors.Additional file
Additional file 1: Power calculations for unadjusted models.
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